BRIEF — Polypeptide Group Definitive Interim Result Of The Public Tender Offer Of Samsung Biologics

Oct 16 (Reuters) — POLYPEPTIDE GROUP AG: Definitive Interim Result Of The Public Tender Offer Of Samsung Biologics Co., Ltd. Samsung Peptide Holds 87.92% Of Polypeptide Share Capital 87.59% Of Polypeptide Shares Tendered Into Offer Minimum Acceptance Rate Condition Of Offer Satisfied No Material Adverse Effect Condition Of Offer Satisfied Samsung Peptide Declares Offer Successful Subject To Remaining Conditions Deal Completion Expected End Of 2026 Or Q1 2027 To Hold Extraordinary General Meeting On Oct 26, 2026 Samsung Peptide To Pursue Squeeze-out And Delisting Of Polypeptide Shares Additional Acceptance Period For Offer From Oct 19 To Oct 30, 2026 Source text:... Further company coverage: PPGN.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)